Form 4: Paradigm Biocapital Advisors LP Reduces Stake in Olema Pharmaceuticals

Paradigm Biocapital Advisors LP reports a decrease in its ownership of Olema Pharmaceuticals common stock following recent transactions.

Summary

• Paradigm Biocapital Advisors LP filed a Form 4 detailing changes in their beneficial ownership of Olema Pharmaceuticals, Inc. common stock on August 1, 2024.
• The transactions involved the disposal of shares at a price of $14.915 per share.
• Paradigm BioCapital International Fund Ltd. disposed of 1,870,499 shares, retaining indirect ownership of 4,720,482 shares.
• Separately managed accounts disposed of 529,501 shares, retaining indirect ownership of 783,118 shares.
• The reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative as a large shareholder is reducing their position, which could be interpreted negatively by the market.

Negatives

• Paradigm Biocapital Advisors LP decreased its holdings in Olema Pharmaceuticals.

Risks

• The reduction in Paradigm Biocapital Advisors LP's stake could indicate a change in their investment outlook for Olema Pharmaceuticals.
• Further sales by Paradigm could put downward pressure on the stock price.

Industry Context

Form 4 filings are a standard part of regulatory compliance for significant shareholders, providing transparency into their transactions and holdings. Large institutional investors like Paradigm Biocapital Advisors often adjust their positions based on their investment strategies and market conditions.

Stakeholder Impact

• Shareholders may react to the news of Paradigm Biocapital Advisors LP reducing its stake.
• The stock price of Olema Pharmaceuticals could be affected by these transactions.

Key Dates